» Articles » PMID: 33930178

Gender-neutral HPV Elimination, Cervical Cancer Screening, and Treatment: Experience from Bhutan

Overview
Publisher Wiley
Date 2021 Apr 30
PMID 33930178
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer is preventable and also curable when detected early and treated adequately, yet it remains a leading cause of morbidity and mortality among women. In Bhutan, cervical cancer is the most common cancer among women. Bhutan was the first country among the low- and middle-income economies to have instituted a national HPV vaccination program, in 2010, and has achieved >90% coverage. In 2019, Bhutan launched a cervical cancer elimination flagship program well ahead of WHO's launch of the global strategy for accelerated elimination of cervical cancer. Bhutan initiated vaccination of adolescent boys and adopted a gender-neutral vaccination program beginning September 2020 through its well-established network of primary healthcare centres. The flagship program aims to screen women aged 30-69 years with HPV testing using liquid-based cytology (LBC) as triaging for screen positive women. For women aged 25-29 years, LBC will be continued as per American Society of Colposcopy and Cervical Pathology guidelines. Colposcopy and treatment will be performed in camps to decrease loss of follow up of screen positive women. This program is also expected to improve early diagnosis of cervical cancer and provide timely and adequate cancer treatment and palliative care services. This article reviews the progress made and the challenges facing the 2030 cervical cancer elimination targets in Bhutan.

Citing Articles

Uptake and determinants of HPV vaccination in South Asia: a systematic review and meta-analysis.

Noreen K, Khalid S, Murad M, Baig M, Khan S Front Public Health. 2024; 12:1453704.

PMID: 39722717 PMC: 11668735. DOI: 10.3389/fpubh.2024.1453704.


Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings.

Man I, Georges D, Basu P, Baussano I J Natl Cancer Inst Monogr. 2024; 2024(67):400-409.

PMID: 39529528 PMC: 11555267. DOI: 10.1093/jncimonographs/lgae035.


Population-level cancer screening and cancer care in Bhutan, 2020-2023: a review.

Dorji T, Wangmo S, Dargay S, Dorji N, Dorjey Y, Pradhan B Lancet Reg Health Southeast Asia. 2024; 24:100370.

PMID: 38444883 PMC: 10910341. DOI: 10.1016/j.lansea.2024.100370.


Cancer screening programs in South-east Asia and Western Pacific.

Wee H, Canfell K, Chiu H, Choi K, Cox B, Bhoo-Pathy N BMC Health Serv Res. 2024; 24(1):102.

PMID: 38238704 PMC: 10797973. DOI: 10.1186/s12913-023-10327-8.


Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?.

Milano G, Guarducci G, Nante N, Montomoli E, Manini I Vaccines (Basel). 2023; 11(6).

PMID: 37376449 PMC: 10303003. DOI: 10.3390/vaccines11061060.